Morgan Stanley
BOLT icon

Morgan Stanley’s Bolt Biotherapeutics BOLT Stock Holding History

Morgan Stanley’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.3K Buy
4,167
+1,022
+32% +$3.9K ﹤0.01% 6968
2026
Q2 		$12.1K Sell
3,145
-44
-1% -$207 ﹤0.01% 6985
2026
Q1 		$12.9K Buy
3,189
+61
+2% +$318 ﹤0.01% 6876
2025
Q4 		$17.1K Hold
3,128
– – ﹤0.01% 6744
2025
Q3 		$16.6K Sell
3,128
-451
-13% -$2.5K ﹤0.01% 6748
2025
Q2 		$20.7K Buy
3,579
+2,998
+516% +$19.8K ﹤0.01% 6642
2025
Q1 		$4.65K Hold
581
– – ﹤0.01% 7009
2024
Q4 		$6.22K Sell
581
-591
-50% -$7.14K ﹤0.01% 6946
2024
Q3 		$15.2K Sell
1,172
-512
-30% -$7.06K ﹤0.01% 6592
2024
Q2 		$25.3K Buy
1,684
+450
+36% +$8.88K ﹤0.01% 6379
2024
Q1 		$34.6K Sell
1,234
-2,736
-69% -$63.4K ﹤0.01% 6344
2023
Q4 		$88.9K Sell
3,970
-4,018
-50% -$78.2K ﹤0.01% 5988
2023
Q3 		$166K Buy
7,988
+6,310
+376% +$154K ﹤0.01% 5666
2023
Q2 		$43K Sell
1,678
-13,642
-89% -$433K ﹤0.01% 6268
2023
Q1 		$426K Buy
15,320
+13,576
+778% +$397K ﹤0.01% 5345
2022
Q4 		$45.3K Sell
1,744
-1,808
-51% -$49.5K ﹤0.01% 6338
2022
Q3 		$105K Sell
3,552
-16,992
-83% -$703K ﹤0.01% 6051
2022
Q2 		$838K Sell
20,544
-646
-3% -$25.1K ﹤0.01% 5124
2022
Q1 		$1.16M Sell
21,190
-1,365
-6% -$91.9K ﹤0.01% 4886
2021
Q4 		$2.21M Buy
22,555
+13,441
+147% +$2.55M ﹤0.01% 4507
2021
Q3 		$2.31M Sell
9,114
-4,703
-34% -$1.33M ﹤0.01% 4454
2021
Q2 		$4.27M Buy
13,817
+13,580
+5,730% +$5.51M ﹤0.01% 3944
2021
Q1 		$156K Buy
+237
New +$154K ﹤0.01% 5797

Other funds holding BOLT

Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return
Pfizer
Pfizer New York $164M AUM 53.62% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $140M AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Nan Fung Group Holdings
Nan Fung Group Holdings Kai Tak, Hong Kong $150M AUM 39.16% 1-Year Est. Return

Morgan Stanley's BOLT Position: Q3 2026 in Review

Morgan Stanley increased its Bolt Biotherapeutics (BOLT) stake by 32% in Q3 2026, buying an estimated $3.9K and bringing the position to 4,167 shares worth $15.3K. The position accounts for ﹤0.01% of the portfolio, ranked #6968.

Morgan Stanley first reported a position in BOLT in Q1 2021 and has held it in 23 quarters since. The position peaked at $4.27M in Q2 2021. 16 funds tracked by Wall St. Rank hold BOLT as of Q3 2026.

  • Morgan Stanley held 4,167 shares of Bolt Biotherapeutics worth $15.3K as of Q3 2026.
  • Morgan Stanley bought 1,022 Bolt Biotherapeutics shares in Q3 2026, an estimated $3.9K.
  • Bolt Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q3 2026, its #6968 holding.
  • Morgan Stanley first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 23 quarters since.
  • Morgan Stanley's Bolt Biotherapeutics position peaked at $4.27M in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2026.

Based on Morgan Stanley's 13F filing for Q3 2026, filed 13 Nov 2026.